Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14101197 | 0.99 | ATM (0.43) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL3227969 | 0.82 | CHRM3 (0.41) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL4742907 | 0.81 | CHRM3 (0.41) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL27795411 | 0.80 | CHRM3 (0.40) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL14101035 | 0.80 | ALDH1A1 (0.40) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL14291866 | 0.76 | ATM (0.42) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL2238914 | 0.75 | CYP2D6 (0.66) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL28257085 | 0.75 | CYP2D6 (0.66) | CHRM3ATML3MBTL1CHRM2CHRM1 | |
| SCHEMBL1109926 | 0.75 | CYP19A1 (0.41) | LMNAKMT2ACYP19A1 | |
| SCHEMBL1109803 | 0.74 | CHRM3 (0.44) | CHRM3ATML3MBTL1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| CN-101657452-A | Hete rocyclic derivatives as the M3 muscarinic receptor | ARGENTA DISCOVERY LTD GB | 2010-02-24 | — | — | CN | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096093-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885ATM 1350/4885L3MBTL1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.